Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). Methods: A cross-sectional study analyzed FL patients who were treated with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance. Results: Of 139 patients, 85 patients received R-CVP and 54 received R-CHOP. The characteristics did not differ significantly between the groups. Only grade 3 of FL was more common in R-CHOP. The complete response rate did not differ significantly between R-CHOP (50/54, 92.6%) and R-CVP (77/85, 90.6%). The number of disease relapses during rituximab maintenance did not differ significantly between the groups (p = 0.798). Therefore, the comparison of progression-free survival (PFS) showed no significant difference: the 3-year PFS rates for R-CVP and R-CHOP were 77% and 85%, respectively (p = 0.567). Although five of 56 hepatitis B virus (HBV) core antibody (anti-HBc)-positive patients experienced HBV reactivation, all cases of HBV reactivation were identified during regular monitoring for HBV DNA in blood, and were successfully managed with antiviral treatment. Conclusions: The survival outcomes of FL patients on rituximab maintenance after responding to R-CVP or R-CHOP were similar. Rituximab-containing immunochemotherapy followed by rituximab maintenance can be safely used for anti-HBc-positive patients if HBV DNA titer in blood can be regularly monitored.
Abstract
Background/Aims: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). Methods: A cross-sectional study analyzed FL patients who were treated with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance. Results: Of 139 patients, 85 patients received R-CVP and 54 received R-CHOP. The characteristics did not differ significantly between the groups. Only grade 3 of FL was more common in R-CHOP. The complete response rate did not differ significantly between R-CHOP (50/54, 92.6%) and R-CVP (77/85, 90.6%). The number of disease relapses during rituximab maintenance did not differ significantly between the groups (p = 0.798). Therefore, the comparison of progression-free survival (PFS) showed no significant difference: the 3-year PFS rates for R-CVP and R-CHOP were 77% and 85%, respectively (p = 0.567). Although five of 56 hepatitis B virus (HBV) core antibody (anti-HBc)-positive patients experienced HBV reactivation, all cases of HBV reactivation were identified during regular monitoring for HBV DNA in blood, and were successfully managed with antiviral treatment. Conclusions: The survival outcomes of FL patients on rituximab maintenance after responding to R-CVP or R-CHOP were similar. Rituximab-containing immunochemotherapy followed by rituximab maintenance can be safely used for anti-HBc-positive patients if HBV DNA titer in blood can be regularly monitored.
참고문헌 (24)
- Morton LM, "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001", Blood, 107, pp.265~276 (2006)
- Friedberg JW, "Follicular lymphoma in the United States : first report of the national LymphoCare study", J Clin Oncol, 27, pp.1202~1208 (2009)
- Yoo KH, "Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial", Int J Hematol, 107, pp.395~404 (2018)
- Cho SH, "Clinical features and survival of patients with follicular lymphoma in Korea", Clin Lymphoma Myeloma Leuk, 16, pp.197~202 (2016)
- Fisher RI, "New treatment options have changed the survival of patients with follicular lymphoma", J Clin Oncol, 23, pp.8447~8452 (2005)
- Vidal L, "Rituximab maintenance for the treatment of patients with follicular lymphoma : an updated systematic review and meta-analysis of randomized trials", J Natl Cancer Inst, 103, pp.1799~1806 (2011)
- Luminari S, "Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma", J Clin Oncol, 36, pp.689~696 (2018)
- Zhang L, "Pros and cons of rituximab maintenance in follicular lymphoma", Cancer Treat Rev, 58, pp.34~40 (2017)
- Seto WK, "Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma : a prospective study", J Clin Oncol, 32, pp.3736~3743 (2014)
- Kim SJ, "Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group", Eur J Cancer, 49, pp.3486~3496 (2013)
- van der Kolk LE, "Rituximab treatment results in impaired secondary humoral immune responsiveness", Blood, 100, pp.2257~2259 (2002)
- Evens AM, "Rituximab-associated hepatitis B virus(HBV)reactivation in lymphoproliferative diseases : meta-analysis and examination of FDA safety reports", Ann Oncol, 22, pp.1170~1180 (2011)
- Liu CJ, "Hepatitis B virus reactivation in patients receiving cancer chemotherapy : natural history, pathogenesis, and management", Hepatol Int, 7, pp.316~326 (2013)
- Hayashi K, "Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy", J Gastroenterol, 51, pp.1081~1089 (2016)
- Dervite I, "Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab", N Engl J Med, 344, pp.68~69 (2001)
- Dong HJ, "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis", J Clin Virol, 57, pp.209~214 (2013)
- Barr PM, "R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study", Lancet Haematol, 5, pp.e102~e108 (2018)
- Bech RS, "Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma", Br J Haematol, 182, pp.297~301 (2018)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Solal-Celigny P, "Follicular lymphoma international prognostic index", Blood, 104, pp.1258~1265 (2004)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Salles G, "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIMA) : a phase 3, randomised controlled trial", Lancet, 377, pp.42~51 (2011)
- Kusumoto S, "Monitoring of hepatitis B virus(HBV)DNA and risk of HBV reactivation in B-cell lymphoma : a prospective observational study", Clin Infect Dis, 61, pp.719~729 (2015)
- Koo YX, "Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative", hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis, 2011, pp.90, 1219~1223